KRIBIOLISA™ Anti-Nivolumab (OPDIVO) ELISA

10 ng/ml - 640 ng/ml

Colorimetric, 450nm

Enzyme Immunoassay for the Quantitative Determination of AntiNivolumab in human serum and plasma. OPDIVO? (nivolumab) is a prescription medicine used in combination with YERVOY? (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the sandwich enzyme immunoassay technique. Nivolumab is pre-coated onto microwells. Samples or standards are pipetted into microwells and antibodies to Nivolumab present in the standards or sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Nivolumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of AntiNivolumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Serum and Plasma

8.75 ng/ml